You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Pharmaceutical Development, Planning, and CMO Identification for the Expedited Advancement of a Scopolamine Multi-Dose-Vial Drug Product

    SBC: CMC PHARMACEUTICALS INC            Topic: CBD212004

    CMC Pharma is proposing this Phase II SBIR to continue the development and testing of a multi-dose vial of a scopolamine hydrobromide trihydrate (Scop-HBT) ready-to-use intramuscular solution formulation. The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) is developing Scop-HBT under the Improved Nerve Agent Treatment System - Centrally Acting ...

    SBIR Phase II 2023 Department of DefenseOffice for Chemical and Biological Defense
  2. Phase Sensitive Millimeter Wave Imaging with Metamaterials

    SBC: SRICO INC            Topic: CBD213002

    SRICO proposes state-of-the-art metamaterial based sensing technology to coherent hyperspectral imaging in the W-band portion of the MMW spectrum. The metamaterial absorber pixel design provides spectrally tailored and phase sensitive vector mode sensing capability critical for W-band imaging. The proposed imaging array features spectrally tailored and deeply sub-wavelength size metamaterial pixel ...

    SBIR Phase II 2023 Department of DefenseOffice for Chemical and Biological Defense
  3. Preclinical Development of a Stable Atropine-Scopolamine Dual Formulation for Medical Countermeasure Readiness

    SBC: CMC PHARMACEUTICALS INC            Topic: CBD181005

    CMC Pharma (Solon, OH) proposes continued development of a stable, fixed-dose combination drug product of atropine and scopolamine as a countermeasure to chemical warfare nerve agents (NA). The combination drug product is expected to exploit complementary pharmacological profiles for optimal anticholinergic activity within the peripheral and central nervous systems. Targeting both the peripheral a ...

    SBIR Phase II 2022 Department of DefenseOffice for Chemical and Biological Defense
  4. Dual Formulation of Atropine-Scopolamine with Enhanced Stability

    SBC: CMC PHARMACEUTICALS INC            Topic: CBD181005

    CMC Pharmaceuticals, Inc. (Cleveland, OH) has proposed developing a stable, combination product of two small molecule drug candidates as a countermeasure to chemical warfare nerve agents (NA). The combination product is expected to exploit complementary pharmacological profiles for optimal muscarinic receptor blockade and anticholinergic activity within the peripheral and central nervous system. I ...

    SBIR Phase II 2020 Department of DefenseOffice for Chemical and Biological Defense
  5. Selection of blood-brain barrier penetrating single domain antibodies as medialcountermeasures for viral induced encephalitis

    SBC: GUILD ASSOCIATES INC            Topic: CBD161004

    Alphaviruses pose significant risks to warfighters where encephalitic virus infection can lead to death. There is no effective treatment foralphavirus induced encephalitis and countermeasures are of high importance. Single domain antibodies (sdAb) are low molecular weightengineered antibody fragments composed of a single heavy-chain variable domain which have proven easier to manipulate and re-eng ...

    SBIR Phase II 2017 Department of DefenseOffice for Chemical and Biological Defense
  6. Phase-Cancelled, Broadband, Graphene-based Impedance Sensor

    SBC: Advratech            Topic: CBD14102

    An innovative phase-cancelled radio frequency/microwave graphene-based impedance chemical gas sensor has been demonstrated in Phase I with the record high sub-ppb sensitivity of NH3 and DMMP in air. Our sensor shows excellent selectivity for sensing NH3 and DMMP in a complex environment, and is capable of in-situ multiplexed sensing. In Phase II, the sensor will be fully integrated on a 3 glass wa ...

    SBIR Phase II 2014 Department of DefenseOffice for Chemical and Biological Defense
  7. Sequencing of Multiple Chemical/Biological Aircraft Decontamination Agents

    SBC: MATERIALS ENGINEERING AND TECHNICAL SUPPORT SERVICES CORP.            Topic: CBD07101

    Under the current SBIR solicitation, the DoD is interested in the development and demonstration of aircraft decontamination processes that are capable of completely detoxifying both chemical and biological warfare agents without increasing susceptibility to corrosion or adversely affecting the performance, properties, or appearance of aircraft materials. Decontamination processes may include indi ...

    SBIR Phase II 2008 Department of DefenseOffice for Chemical and Biological Defense
  8. Portable System for Immediate Decon of Interior Spaces

    SBC: MATERIALS ENGINEERING AND TECHNICAL SUPPORT SERVICES CORP.            Topic: CBD05108

    The United States Government has spent hundreds of millions of dollars developing decontamination capabilities to protect our military personnel and equipment from chemical warfare agents. With over 20 countries now having the capability to manufacture and use biological warfare agents, and the reality of the events involving the use of Anthrax on US soil after September 11, 2001, decontamination ...

    SBIR Phase II 2006 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government